Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group

Cancer

Volumn 119, Issue 11, 2013, Pages 1994-1998

  Galsky, Matthew D ^a   Hendricks, Ryan ^a   Svatek, Robert ^b   Bangs, Rick ^c   Hoffman Censits, Jean ^d   Clement, Jessica ^e   Dreicer, Robert ^f   Guancial, Elizabeth ^g   Hahn, Noah ^h   Lerner, Seth P ⁱ   O'Donnell, Peter H ^j   Quale, Diane Zipursky ^c   Siefker Radtke, Arlene ^k   Shipley, William ^l   Sonpavde, Guru ^m   Vaena, Daniel ⁿ   Vinson, Jacob ^o   Rosenberg, Jonathan ^o  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Bladder Cancer Advocacy Network   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ UNIVERSITY OF IOWA   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

bladder cancer; clinical trials; metastatic; urothelial cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; UNCLASSIFIED DRUG;

ANALYSIS; ARTICLE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CANCER RESEARCH; CRITICAL ANALYSIS; HUMAN; METASTASIS; METASTATIC UROTHELIAL CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUMOR INVASION; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMEDICAL RESEARCH; CISPLATIN; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84878017704     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27973     Document Type: Article

References (13)

1. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988; 139: 461-469.
2. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK,; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party; European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-2177.
3. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
4. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10: 1066-1073.
5. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
6. Dreicer R,. The future of drug development in urothelial cancer. J Clin Oncol. 2012; 30: 473-475.
7. Richter S, Sridhar SS,. New directions for biologic targets in urothelial carcinoma. Mol Cancer Ther. 2012; 11: 1226-1235.
8. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC,. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011; 364: 852-860.
9. Zarin DA, Tse T, Ide NC,. Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med. 2005; 353: 2779-2787.
10. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem MA,. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012; 307: 1838-1847.
11. Morris MJ, Basch EM, Wilding G, et al. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009; 7: 51-57.
12. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJs,. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009; 86: 97-100.
13. National Cancer Institute. National Cancer Institute Fact Sheet: Cancer Research Funding. http://www.cancer.gov/cancertopics/factsheet/NCI/research- funding. Accessed October 6, 2012.